Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.

Area of Science:

• Pediatric Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Neuroblastoma survival rates remain suboptimal compared to other childhood cancers.
• Current treatments, including [123I]metaiodobenzylguanidine (MIBG) imaging and [131I]MIBG therapy, target the norepinephrine transporter but require optimization.
• Alternative molecular targets like somatostatin receptors and disialogangliosides offer potential but are largely experimental.

Purpose of the Study:

• To convene experts in molecular imaging and radiotherapy for neuroblastoma.
• To discuss strategies for improving treatment outcomes and patient access.
• To identify and address barriers hindering progress in neuroblastoma therapy.

Main Methods:

• A multidisciplinary workshop involving scientists and clinicians from Europe and North America.
• Discussion of current and novel radionuclide imaging and therapy approaches.
• Exploration of combination therapies including radiotherapy, immunotherapy, and DNA repair inhibitors.

Main Results:

• Identified development of alternative vectors targeting somatostatin receptors and disialogangliosides.
• Considered novel isotopes (alpha and Auger electron emitters) for targeted radionuclide therapy.
• Highlighted the need for optimized combination strategies and addressed barriers like isotope supply and clinical facilities.

Conclusions:

• Further development and assessment of innovative molecular imaging and radionuclide therapy are crucial for neuroblastoma.
• Addressing challenges in radiopharmaceutical production and clinical trial infrastructure is essential.
• Multidisciplinary collaboration is key to advancing neuroblastoma treatment outcomes.